Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC) - Adams, S; Loi, S; Toppmeyer, D (Cancer Res, 2018)